MS Therapeutics

MS Therapeutics is a specialty pharma company engaged in the development and commercialisation of therapeutic agents for people with MS. MS Therapeutics is focused on developing and commercializing both disease-modifying drugs and therapies to treat the symptoms of multiple sclerosis and related disorders. The MS market is currently served by six anti-inflammatory drugs (3 of which are b-interferons) but theyare all only partially effective in the relapsing-remitting phase of the disease. MS Therapeutics is progressing useful enhancements and innovative improvements to therapeutic regimens which have some existing familiarity and understanding amongst regulators, patients and prescribers.